Cover
Cover | Aug. 12, 2024 |
Entity Addresses [Line Items] | |
Document Type | 8-K/A |
Amendment Flag | true |
Amendment Description | As previously reported in the Current Report on Form 8-K filed by Citius Oncology, Inc., a Delaware corporation (the “Company”), on August 16, 2024 (the “Original Report”), on August 12, 2024 (the “Closing Date”), the Company completed the previously announced business combination (the “Closing”) pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 23, 2023, by and among Citius Pharmaceuticals, Inc., a Nevada corporation, Citius Oncology Sub, Inc., a Delaware corporation (“SpinCo”), TenX Keane Acquisition, a Cayman Islands exempted company (“TenX”, now Citius Oncology, Inc., a Delaware corporation) and TenX Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of TenX, and the related transaction documents described therein (the “Business Combination”). |
Document Period End Date | Aug. 12, 2024 |
Entity File Number | 001-41534 |
Entity Registrant Name | Citius Oncology, Inc. |
Entity Central Index Key | 0001851484 |
Entity Tax Identification Number | 99-4362660 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 11 Commerce Drive |
Entity Address, Address Line Two | 1st Floor |
Entity Address, City or Town | Cranford |
Entity Address, State or Province | NJ |
Entity Address, Postal Zip Code | 07016 |
City Area Code | 908 |
Local Phone Number | 967-6677 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock |
Trading Symbol | CTOR |
Entity Emerging Growth Company | true |
Elected Not To Use the Extended Transition Period | false |
Former Address [Member] | |
Entity Addresses [Line Items] | |
Security Exchange Name | NASDAQ |